Scancell (SCLP) Competitors

Oxford Biomedica (LON:OXB) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Which has preferable valuation and earnings, OXB or SCLP?

Scancell has lower revenue, but higher earnings than Oxford Biomedica. Scancell is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£98.31M	3.30	-£143.51M	-£134.59	-2.27
Scancell	N/A	N/A	-£6.75M	-£0.65	-12.30

Is OXB or SCLP more profitable?

Scancell has a net margin of 0.00% compared to Oxford Biomedica's net margin of -145.98%. Scancell's return on equity of 98.74% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-145.98%	-202.50%	-12.67%
Scancell	N/A	98.74%	-45.28%

Which has more risk & volatility, OXB or SCLP?

Oxford Biomedica has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Scancell has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500.

Does the MarketBeat Community believe in OXB or SCLP?

Oxford Biomedica received 172 more outperform votes than Scancell when rated by MarketBeat users. However, 74.50% of users gave Scancell an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote.

Company	Underperform	Outperform
Oxford Biomedica	Outperform Votes 359 66.73%	Underperform Votes 179 33.27%
Scancell	Outperform Votes 187 74.50%	Underperform Votes 64 25.50%

Do institutionals and insiders hold more shares of OXB or SCLP?

64.1% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 46.5% of Scancell shares are owned by institutional investors. 21.2% of Oxford Biomedica shares are owned by insiders. Comparatively, 5.0% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer OXB or SCLP?

Oxford Biomedica currently has a consensus target price of GBX 560, suggesting a potential upside of 83.31%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to OXB or SCLP?

In the previous week, Scancell had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Scancell and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 1.47 beat Scancell's score of 0.00 indicating that Oxford Biomedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scancell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oxford Biomedica beats Scancell on 11 of the 17 factors compared between the two stocks.